AD
Aditya Birla Sun Life Quant Fund Direct Growth
Latest NAV
+2.70% 1Y
Sign In to Add to Portfolio
Benchmark: Nifty 200 TRI
Expense ratio
1.32%
AUM
₹2,035 Cr
Min SIP
₹500
Min lump sum
₹500
1Y
+2.70%
3Y (ann.)
+0.00%
5Y (ann.)
+0.00%
Launched
Jun 2024
Where the NAV sits & how risky it is
₹9.91
52-week range
at 47%
₹9.91
Low 20 Jan 2025₹9.12
High 07 Aug 2026₹10.80
Risk level
Very High
Low
Very high
NAV history
01 Jul 2024
Since inception
05 Oct 2026
Returns by period
1W
-4.36%
1M
-7.23%
3M
-4.26%
6M
+6.58%
1Y
+2.70%
3Y
+0.00%
5Y
+0.00%
3Y and 5Y returns are annualised.
Return calculator
You invest
—
Est. gain
—
Est. value
—
Invested Gain
Invested
Projected value
min SIP ₹500
Estimate only. It assumes the selected past return repeats every year; 3Y and 5Y figures are taken as annualised. Actual returns vary and are not guaranteed.
Where your money goes
AS OF 31 MAY 2026
Equity 99.51%
Cash & other 0.82%
Sector split
Country split
Top 5 hold 18.7%
Top 10 hold 35.0%
47 equity holdings
Equity holdings
(top 30)
| # | Holding | Sector | Country | Weight | YTD |
|---|---|---|---|---|---|
| 1 | Federal Bank
INE171A01029 |
Financial Services Banks - Regional |
India |
4.07%
|
+15.97% |
| 2 | Marico
INE196A01026 |
Consumer Defensive Household & Personal Products |
India |
3.74%
|
+8.02% |
| 3 | Grasim Industries
INE047A01021 |
Basic Materials Building Materials |
India |
3.68%
|
+9.21% |
| 4 | Ashok Leyland
INE208A01029 |
Industrials Farm & Heavy Construction Machinery |
India |
3.66%
|
-21.27% |
| 5 | State Bank of India
INE062A01020 |
Financial Services Banks - Regional |
India |
3.52%
|
+3.65% |
| 6 | Apollo Hospitals
INE437A01024 |
Healthcare Medical Care Facilities |
India |
3.51%
|
+20.74% |
| 7 | Hindalco Industries
INE038A01020 |
Basic Materials Aluminum |
India |
3.29%
|
+15.52% |
| 8 | Bharti Airtel
INE397D01024 |
Communication Services Telecom Services |
India |
3.21%
|
-15.34% |
| 9 | Sun Pharmaceutical
INE044A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.20%
|
+4.97% |
| 10 | Torrent Pharmaceuticals
INE685A01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.15%
|
+19.75% |
About this scheme
The investment objective of the Scheme is to generate long term capital appreciation by investing in equity and equity related securities based on quant model theme . The Scheme does not guarantee/indicate any returns. There is no assurance that the investment objective of the Scheme will be achieved.
Fund manager(s): Harish Krishnan, Kartikeya Singh
Exit load: Exit load of 0.50%, if redeemed within 90 days.
Scheme snapshot
VR Rating
MS Rating
Plan
Growth
Type
DIRECT
Inception
28 Jun 2024
Lump-sum min
₹500
SIP
Purchase
Switch
STP
SWP
Similar schemes
RANKED BY 1Y RETURN
Nippon India Taiwan Equity Fund Direct Growth
1▲ 118.8 pts ahead of this fund
Franklin Asian Equity Fund Direct Growth
2▲ 30.7 pts ahead of this fund
Nippon India Japan Equity Fund - Direct Plan - Growth Plan - Bonus Option
3▲ 27.9 pts ahead of this fund
Nippon India Japan Equity Fund Direct Growth
4▲ 27.9 pts ahead of this fund
Bank of India Small Cap Fund Direct Growth
5▲ 26.5 pts ahead of this fund
TRUSTMF Small Cap Fund Direct Growth
6▲ 26.4 pts ahead of this fund